Durham-based The Aurora Funds (www.aurorafunds.com) announced that the firm's Doug Gooding will become the President of Regado Biosciences, an early stage biopharmaceutical company and Aurora portfolio company. Durham-based Regado is focused on the discovery, development and commercialization of antidote-controlled therapeutics. As part of this transition, Gooding will become a Venture Partner with Aurora.
Since joining Aurora in April 2001, Gooding has worked primarily with Aurora's life science portfolio, specifically in the areas of biotechnology, agriculture and biopharmaceuticals. In his new role as Venture Partner, Gooding will continue to be actively involved as a Board member with the companies in which he led investments, including two RTP-based companies, CropSolution and Metabolon, as well as TissueInformatics, a Pittsburgh-based biotechnology company.
The Aurora Funds has been a CED member since 1995.
Regado Biosciences has been a CED member since 2003.